Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Autolus Therapeutics ( (AUTL) ) has shared an announcement.
On February 24, 2025, Autolus Therapeutics announced the resignation of Andrew Mercieca, Vice President of Finance and principal accounting officer, effective August 2025. His departure is amicable and not due to any disagreements with the company. On April 3, 2025, the Board appointed Rob Dolski, the current CFO, as the new principal accounting officer, consolidating his roles without additional compensation, indicating a seamless transition in leadership.
More about Autolus Therapeutics
Autolus Therapeutics operates in the biotechnology industry, focusing on the development of advanced therapies for the treatment of cancer.
YTD Price Performance: -40.30%
Average Trading Volume: 1,254,064
Technical Sentiment Signal: Strong Buy
Current Market Cap: $375.2M
See more insights into AUTL stock on TipRanks’ Stock Analysis page.